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Background: There are a number of studies dedicated to characteristics of sedation, but these studies are mostly
bound to western country practices. The aim of this study is to describe the characteristics of patients who suffered
from cancer and who had been sedated until their death in Shanghai, China.
Methods: Retrospective medical data of 244 terminally ill cancer patients including 82 sedated patients were
collected. Data collected included demographic characteristics, disease-related characteristics and details of the sedation.
Results: In sedated cases, patients and/or caregivers gave the consent to start palliative sedation due to unmanageable
symptoms. On average, sedation was performed 24.65(±1.78)hours before death. Agitated delirium and dyspnea were the
most frequent indications for palliative sedation. There was no significant difference in survival time from admission till
death between sedated and non-sedated patients (p > 0.05).
Conclusions: Palliative sedation is effective for reducing terminally ill cancer patients’ suffering without hastening death.
Prospective research is needed to determine the optimal conditions for Chinese patients including indications, decision
making process, informed consent, cultural and ethical issues, type of sedation and drugs.
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Mini abstract
Palliative sedation is effective for reducing the suffering
of terminally ill cancer patients without hastening death.
Agitated delirium and dyspnea were the most frequent
indications for palliative sedation.
Terminally ill cancer patients may suffer severe refrac-
tory symptoms in their last weeks of life despite having
received palliative treatments. Palliative sedation (PS) is
one of the optimal palliative therapies used for these pa-
tients who are resistant to any other forms of treatments
[1,2]. According to the definition proposed by the National
Hospice and Palliative Care Organization (NHPCO), PS is
the lowering of patients’ consciousness using medications
for the express purpose of limiting patients’ awareness of
suffering that is intractable and intolerable, or sufferings
that patients perceive to be unbearable, which has not ad-
equately respond to any interventions and for which* Correspondence: wenwucheng@yahoo.com
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cal [3]. PS can be performed intermittently or continuously
until death, and that the depth of sedation can vary from a
lower level of consciousness to complete unconsciousness.
PS is frequently used in end-of-life care for terminally
ill cancer patients in Western countries. Guidelines and
recommendations have been published by different orga-
nizations according to different cultural backgrounds
and practices such as NHPCO, European Association
for Palliative Care(EAPC), the Royal Dutch Medical As-
sociation [4-6]. Several inconsistencies exist amongst the
guidelines with regards to the initiation, the level, the
pattern and even the continuation or discontinuation of
life-sustaining therapies. These discrepancies can be at-
tributed to divergent PS definitions, ethical and clinical
factors in different areas [7,8].
China is a traditional East Asian country with a unique
view on end-of-life issues [9]. Traditional Chinese cul-
ture dictates that a good death can only be obtained if
consciousness is kept clear near the end of life. For
Chinese patients and their families, they may be con-
cerned about the doctrine of double effects of PS. PSs is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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assisted suicide because of its potential life-shortening
effect. Therefore, it is challenging to follow the western
recommendations for palliative care while taking into
account the differences in Chinese culture.
There are currently no guidelines or any other rules
for PS for Chinese cancer patients. There are not even
any formal studies of PS for terminally ill cancer pa-
tients. Thus, we present an analysis of PS practice from a
Tertiary Metropolitan Cancer Center in Shanghai, China.
This study aims to summarize the characteristics of
patients who were sedated for refractory symptoms
and describe and reflect on some different practices in
Mainland China.
Methods
Palliative sedation policy and decision making process in
the department
Fudan University Shanghai Cancer Center (FUSCC) is
an 800-bed tertiary cancer center. The Integrated Ther-
apy Department (used called Palliative Care Department)
with a 12-bed inpatient ward was established in 2006 to
provide supportive care for advanced cancer patients
who cannot undergo any anti-cancer therapy. In this de-
partment, daily multidisciplinary meetings are held with
palliative care physicians, medical oncologists, nurses, and
weekly meetings with an anesthesiologist, a psychiatrist,
and social workers.
The sedation was performed according to the sedation
routine of our department, which was established through
previous experience and clinical research [10], and is
described below. PS was potentially indicated for patients
with refractory physical symptoms. Initially, intermittent
sedation was used. The decision to transition from inter-
mittent to continuous sedation for these patients was based
on the prevalence of uncontrolled symptoms. Once PS was
implemented, the patients’ vital signs were monitored by
nurses regularly during the initial 24 hours. Cessation of
sedation was considered when the symptoms became man-
ageable. The indications to start PS, the drugs used for and
the duration of the sedation, the decision-making process
were recorded in patients’ medical records.
Every patient admitted to the in-patient department of
the FUSCC has the option to sign a letter of authorization
giving family members the right to make medical deci-
sions for him should he lose his decision-making capacities.
For patients lacking decisional capacities, permission was
obtained from a legal proxy. The decision-making process
for PS was undertaken by a multi-professional palliative care
team with more than 3 senior attending palliative physicians
to discuss whether PS would ease the patients’ sufferings. PS
was recommended by a patients’ attending physician accord-
ing to the patients’ symptom sufferings and estimated
survival length time. A written informed consent formwas signed when physicians and patients and/or autho-
rized family members reached an agreement to imple-
ment PS after the aims, benefits and risks of PS were
informed to patients and/or authorized family. After
the written informed consent form was signed by the
patients and/or authorized family, sedation drugs were
prescribed by the patients’ attending physician.
Patients and measurements
This study was approved by the Institutional Review
Board of the Cancer Center. A systematic retrospective
analysis was performed of the medical records of those
who died in the Integrated Therapy Department in FUSCC
between March 2007 and September 2011.
We reviewed the medical records of the 244 patients
through the Union Medical System (UMS) of FUSCC.
(The UMS is the electronic medical records system
which containing all the medical information of patients
in the FUSCC.) Three physicians reviewed the medical
records of patients to select patients who received PS for
the purpose of palliation. Patients who received benzodi-
azepines (such as estazolam) for insomnia as symptom
control were excluded from this research. Our unit did
not use PS for management of anxiety or existential suf-
fering alone.
Demographic variables and details of PS of these pa-
tients were gathered and reviewed. The demographic
variables included sex, age, diagnosis, metastatic sites
and functional/performance status at the day of admis-
sion as measured by using the Karnofsky Performance
Scale (KPS) ranging from 100 (normal) to 0 (dead).The
details of sedation records included the indication to
start PS, the duration of the PS, the sub-type of PS,
drugs and dosage used, and the administration route of
PS. The duration of PS was defined as the number of
hours elapsed between the start of PS until it was stopped
or the patients died. The sub-type of PS was intermittent
or continuous sedation. Survival time was defined as the
time between the day of admission to the hospital and the
day patients died. The total survival time was defined as
the time between the day patients were diagnosed and the
day patients died.
The informed consent forms were retrieved through
the UMS to evaluate the decision-making process of pa-
tients and their family caregivers.
Statistical analysis
Data management and statistical analysis were per-
formed using SPSS 16.0 software. Frequency distribu-
tions were used to describe the demographic data and
the distribution of each variable. A Chi-squared test was
used to make comparisons with respect to categorical
variables, and Fisher’s exact test was used if sample size
criteria were not met for Chi-squared approximation.
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pare the survival time between sedated and non-sedated
patients. A p-value less than 0.05 was considered statisti-
cally significant.
Results
Demographic and survival differences between sedated
and non-sedated patients
General characteristics of enrolled patients are shown in
Table 1. 244 terminally ill cancer patients were included
in this study. 51.23% were men. The median age was
63 years old (range 24 to 93 years old). Lung cancer was
the most common diagnosis (14.8%). 156 of 244 (63.93%)
patients had metastasis. Lung, liver and bone were the
most prevalent metastatic sites, and 55 patients (22.54%)
had more than 3 sites of metastasis. The most frequent
KPS was 20, indicating that patients were mainlyTable 1 Demographic and survival difference between
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Breast cancer 26 8/9.8% 18/11.1%
Stomach cancer 33 9/11.0% 24/14.8%
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* Survival time means the days since administration till death.
# Total Survival time means the months since diagnose till death.bedbound and required assistance with care. The
mean survival time was 23.54 days (95% CI: 22, 27),
the median survival time was 19 days (95% CI: 17, 21),
and the range was 1–139 days.
There were no differences between sedated and non-
sedated patients in gender, age, and primary cancer sites.
The median KPS of the sedated patients was lower than
that of non-sedated patients (20 and 30, respectively),
but the difference was not significant (p > 0.05). The
similar characteristics of the sedated and non-sedated
patients indicated that the survival difference of the two
groups could be compared. The sedated patients had a
mean survival time of 27.44 days while the non-sedated
patients had a mean survival time of 21.56 days. There
was no statistically significant difference between the
survival time of the two groups (p = 0.066). Sedated pa-
tients had a significantly longer total survival time than
non-sedated patients (p = 0.002).Details of sedation
The details of sedation are shown in Table 2. 54 out of
82 (65.85%) patients began sedation 0–24 hours before
death and 18 (21.95%) patients began sedation 25–48
hours before death. On average, sedation began 24.65 hours
(SD ± 1.78, range: 2-71hours) before death. The median
time was 22 hours. No patients stopped receiving sedation
once the sedation had begun.
All 82 patients were intermittently sedated at the begin-
ning, allowing minimal contact with relatives. 20 patients
transferred from intermittent to continuous sedation be-
tween the start of sedation and death. The mean transfer
point was 13.45 hours (SD ± 13.5) before death. The most
commonly used drugs were diazepam in 59 patients, halo-
peridol in 48 patients and chlorpromazine in 9 patients.
34 patients used more than one kind of drug.
Diazepam and haloperidol were used for intermittent PS.
Chlorpromazine was used for intermittent PS or in com-
bination with other drugs for continuous PS. Morphine
was used in combination with other drugs for 12 of the 82
sedated patients. The most frequent route of administra-
tion was intramuscular injection.
Agitated delirium and dyspnea were the most frequent
indications for starting PS. 39 received sedation for agitated
delirium, 35 for dyspnea, and 12 patients for uncontrolled
pain.Decision making
All 82 patients had signed the letter of authorization at
admission. In 65 cases only the caregivers’ consent was
received. This was frequently related to cognitive impair-
ment of various etiologies. Communication was no lon-
ger possible or was reduced to the most basic issues
with these patients. In 7 cases only the patient’s consent
Table 2 Details of palliative sedation in 82 patients
Variables N
Frequency of palliative sedation (N/%)
Intermittently 82(100%)









Mean hour (SD) 24.65(±1.78)
Median hour (range) 22 (2–71)
Time between the start of sedation and death
0-24 hours before death (%) 54 (65.85%)
24-48 hours before death (%) 18 (21.95%)
>48 hours before death (%) 10 (12.20%)






Caregivers consent only 65
Patientss’ consent only 7
Both the caregivers and patients consent 10
* 34 patients used more than one kind of drugs.
※ The number in the route was 84 because 2 patients received both
intravenous and intramuscular injection.
#10 patients suffered more than one indication for the PS. Others included
uncontrolled nausea and vomiting.
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givers’ consents were received.
Discussion
This study provided the overview of the characteristics
of PS implementation in Mainland China. Our study re-
vealed that 33.6% of the patients who died in the Inte-
grated Therapy Department received some form of PS.
The cultural values of each society play an important
role in shaping the practice of sedation according to dif-
ferent definitions, cultural understandings and traditions.
This is reflected in several dimensions of the details of
PS at FUSCC.
There was no statistically significant difference in sur-
vival time between patients who underwent sedation and
those who did not. This indicated that PS had no potentiallife-shortening effect in consist with previous researches
[11-15]. Sedation patients had a significantly longer total
survival time than non-sedated patients in our study. This
may be explained by that patients who had a longer dis-
ease journey suffered more and had the more desire to re-
duce the suffering.
In this study, the frequency of sedation was 33.6%
(82/244), similar with a review enrolled 10 studies with
1807 patients (34.4%) [2]. But our rate of PS is higher
than that reported in a Taiwanese study more than
10 years ago (27.9%) and in a Singaporean study (22.6% at
48 hours before death) in 2012 [16,17]. Although the
Taiwanese, Singaporeans and Mainland Chinese share
a similar cultural background, the difference still ex-
ists. This difference can be explained by the large vari-
ability of PS frequency, which was reported as 1-88%
according to cultural understanding of PS and different
time period examined [18,19].
The median duration of PS in our department was
22 hours, while the median time in previous studies var-
ied from 21.6 to 48 hours [12,20-23]. 65.85% of our sedated
patients died within 24 hours. The potential explanation
for shorter duration and late initiation maybe was that pa-
tients were usually at the stage of impending death when
they started to receive PS. From the physicians’ perspective,
estimating the patients’ remaining survival time was con-
sidered to be a difficult and challenging task. From the pa-
tients and caregivers’ perspective, sedation was seen as
having a potential life-shortening effect. These reasons may
have lead to PS being started too late and patients suffering
needlessly at the end of life.”
As found in other studies, agitated delirium and dys-
pnea were the most frequent symptom indications for
PS [22-24]. Although delirium was consistently the most
common indication for PS in other studies, there was
wide variability in its occurrence as an indicator (ranging
from 13.8%-91.3%) [2]. In our practice, for patients with
agitated delirium, the underlying cause was treated first
with re-balancing water and electrolytes and provision of
psychological support. Nevertheless, 39 patients required
sedation for uncontrolled terminal stage agitation in our
research. In this study, the frequency of pain as the indi-
cator was lower than reported in previous researches
[25-27], because PS was used for pain only after failure
of interventions including opioids switching and escal-
ation and other adjuvant drugs in our department.
In this study, Diazepam, a kind of benzodiazepine, was
the drug used most often for sedation. It was the first
choice because midazolam, the most popular drug for
PS in Western practice, is not available in our depart-
ment [28,29]. The second most used drug, haloperidol
was not in the list of recommended drugs for PS accord-
ing to the EAPC and NHAPC guidelines, but in many
studies, it was still the first choice for patients with
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in 26% of sedated patients according to the review of 10
studies which enrolled 1807 patients combined [2]. Mor-
phine was also not included in the list of the recommended
drugs, but it may have produced an effect alongside
sedation.
Continuous palliative sedation is increasingly accepted
as a part of palliative care therapy in many countries
[30]. Studies show that continuous sedation was per-
formed in 2.5%-15% of all deaths in Europe [31-34].
8.2% (20/244) patients in our study received continuous
sedation. The decision to switch from intermittent to
continuous sedation for these patients was based on the
prevalence of uncontrolled symptoms. This indicated that
continuous sedation can be acceptable for Chinese pa-
tients after sufficient discussion with family caregivers in
some situations. As interfering with the dying process by
causing patients to become unconscious, even with the in-
tent to relieve physical suffering, was viewed as inhumane
in Chinese traditional society, these results reflect to some
extent a shift in end-of-life values.
The decision-making process also reflected the cul-
tural values of each society. The reported degree of in-
volvement of and information given to patients and
families varies considerably [35,36]. Autonomy is one of
the most valued rights in Western countries, especially
in the United States, while in Eastern countries, illness is
considered a family event rather than an individual oc-
currence [37]. Previous studies revealed that Asian pa-
tients prefer to leave end-of-life decisions to their family
caregivers [38]. The family caregivers played a more im-
portant role in the decision-making process than pa-
tients. Liu JM’s research found that Chinese patients are
less likely to sign their own do-not-resuscitate (DNR) or-
ders [39]. The reason is that according to cultural trad-
ition in China, the individual is viewed as embedded in
the family and society. The decision making process for PS
in our department is in accordance with this phenomenon.
In our research, when patients were not conscious enough
to make the decision for PS, we obtained informed consent
only from their caregivers. Although to some extent, deci-
sions from caregivers reflected the wishes of the patients,
there was still potential for an ethical conflict when thera-
peutic decisions had to be made for these patients [35].
The key drawback of this study was that the retrospect-
ive research method had some limitations. Firstly, there
were no standard form to record details of PS. Secondly,
the information about the assessment of the symptom re-
lief after receiving PS was insufficient to analyze. Another
limitation is that as the data we gathered was in one can-
cer center, the result of this study cannot be extrapolated
to other care settings in mainland China. To reduce the
bias, studies involving multiple centers should be carried
out in the future.Conclusion
To our knowledge, this research is the first study fo-
cused on the practice of PS for terminally ill cancer pa-
tients in mainland China. We recognized that PS is
effective for reducing the suffering of these patients
without hastening death. Prospective research is needed
to determine the optimal conditions for Chinese patients
including indications, decision making process, informed
consent, cultural and ethical issues, type of sedation and
drugs.
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